Download Document

12510 Prosperity Blvd.,
Suite 310
Silver Spring, MD 20904
Phone (917) 595 2850
Fax (917) 595 2851
Company Overview
Stock Information
Nuvilex, Inc. (NVLX) is an innovative development stage
pharmaceutical company committed to implementing a
novel cellulose-based live-cell encapsulation technology
to develop treatments for various cancers and for
diabetes. The live-cell encapsulation technology
employed by Nuvilex encloses living cells in protective
“cocoons” the size of the head of a pin - drugs are not
encapsulated using this technology.
Ticker: NVLX/ OTC.QB
Mkt. Cap.: 121M
The cell encapsulation technology used by Nuvilex can be
classified as a “platform” upon which treatments for
different indications may be built. Depending on the type
of cells utilized, the encapsulated cells can be employed
in developing treatments for serious, debilitating and lifethreatening diseases. For example, for cancer, the livecell encapsulation technology is combined with new or
established anticancer drugs
Company
Highlights
*a/o 2/4/14
Recent Close: $0.21*
Avg. Vol.: 3,860,640
52 Wk. Range: $0.22 - $0.03
Executive Management
We have an expert team of industry leaders with the vision
and drive to successfully unlock the potential of Nuvilex’s
products and pipeline.
Exclusive worldwide rights to use live-cell encapsulation
technology to develop treatments for cancer and diabetes;
poised to deliver multiple products.
An eighty million dollar market cap and an average stock
trading volume of over 2,500,000.
A product in late-stage development that employs a wellknown cancer drug.
From the core-technology of cellulose-based live-cell
encapsulation, multiple treatment areas emerge,
encompassing billion dollar markets annually.
Nuvilex, Inc. has assembled a team
experienced in cancer treatment development
and live-cell encapsulation technology.
Kenneth L. Waggoner
President and CEO
Dr. Gerald W. Crabtree
Chief Operating Officer
Dr. Robert F. Ryan
Chief Science Officer
Patricia Gruden
Chairman of the Board
and Chief Financial Officer
nuvilex.com
Notice Regarding Forward-Looking Statements -- This fact sheet contains forward-looking statements as that term is defined in Section 27A of the United States
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this fact-sheet, which are not purely historical, are forward-looking
statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in
any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of publication of this fact sheet, and we assume
no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking
statements. Although we believe that the beliefs, plans, expectations and intentions contained in this fact sheet are reasonable, there can be no assurance that such
beliefs, plans, expectations or intentions will prove to be accurate.
Meadows Corporate Park I
12510 Prosperity Blvd.,
Suite 310
Silver Spring, MD 20904
Phone (877) 958 7616
Fax (917) 595 2851
Company Pipeline
Media Coverage
Live-Cell encapsulation plus ifosfamide (IFEX®) for pancreatic cancer
Pre-Clinical
Phase1
Phase2
Phase3
Live-Cell Encapsulation plus Cyclophosphamide for Breast Cancer
Pre-Clinical
Phase1
Phase2
Phase3
Live-Cell Encapsulation plus Insulin-producing Cells for Diabetes
Pre-Clinical
Phase1
Phase2
Phase3
Live-Cell -cell encapsulation plus cannabinoids from
Cannabis for Cannabinoids for Brain and Pancreatic
Cancers
Pre-Clinical
Phase1
Phase2
Phase3
Article on Nuvilex,
Inc. on Sept. 23,
2013, entitled
“Biotechs Are Back
in Favor: Following
a Plethora of
Positive
Developments”
Nuvilex mentioned in
widely read issue on
September 11th 2013
in an article titled,
“Feds Patented
Medical Pot... While
fighting it”
Medical Marijuana and Major Diseases
The use of Cannabis for medicinal purposes dates back over 3,000 years. Originally introduced to western
medicine in the early 1840’s, Cannabis has been touted for its reported analgesic, sedative, anti-inflammatory,
anticonvulsant, and anti-spasmodic effects. Since the 1970’s,
cannabinoids from Cannabis have been recognized for their ability to
alleviate nausea and vomiting as well as relieve various types of pain.
Since 2001, interest in the anticancer properties of cannabinoids has
increased significantly. In vitro, cannabinoids have demonstrated
efficacy combating brain, lymphoma, pancreatic, skin, breast, thyroid,
colorectal and prostate cancer cells. In animals, cannabinoids reduced
tumor growth and metastasis and were shown to be antiangiogenic.
In 2006, in a small, early-phase clinical study, THC proved beneficial in
treating glioblastoma multiforme, a type of brain tumor, when
non-psychoactive doses were used.
nuvilex.com
Notice Regarding Forward-Looking Statements -- This fact sheet contains forward-looking statements as that term is defined in Section 27A of the United States
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this fact-sheet, which are not purely historical, are forward-looking
statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in
any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of publication of this fact sheet, and we assume
no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking
statements. Although we believe that the beliefs, plans, expectations and intentions contained in this fact sheet are reasonable, there can be no assurance that such
beliefs, plans, expectations or intentions will prove to be accurate.
Meadows Corporate Park I
12510 Prosperity Blvd.,
Suite 310
Silver Spring, MD 20904
Phone (877) 958 7616
Fax (917) 595 2851
Live-cell Encapsulation
Live-Cell Encapsulation plus Cyclophosphamide for Breast Cancer
Nuvilex’s breast cancer treatment uses the cellulose-based live-cell encapsulation
technology with the well-known and widely-used cancer drug cyclophosphamide.
Cyclophosphamide (CYTOXAN®) is activated the same way as ifosfamide. Nuvilex
aims to treat diabetes by encapsulating insulin-producing cells using the cellulose
-based live-cell encapsulation technology, and then implanting them into diabetic
patients to serve as a type of artificial pancreas.
Live-Cell Encapsulation plus Insulin-producing Cells for Diabetes
The cellulose-based live cell encapsulation technology will be used with cannabinoids
from Cannabis to develop treatments for some of the deadliest forms of cancer,
View of a Single Capsule
particularly brain cancer and pancreatic cancer.
Live-Cell Encapsulation plus Cannabinoids for Cancer
Research done over the past decade in the cancer area with medical marijuana has shown that cannabinoids
are effective in the laboratory and in animals against a wide variety of cancer cells. Studies have shown that
cannabinoids can kill cancer cells and prevent the spread and regrowth of established cancers.
Live-Cell Encapsulation plus Ifosfamide for Pancreatic Cancer
Nuvilex’s pancreatic cancer treatment utilizes proprietary cellulose-based
live-cell encapsulation technology, together with the long-known and
widely used anticancer drug ifosfamide (IFEX®).
Ifosfamide, administered intravenously, can cause severe drug-related
toxicities, particularly to organs of the urinary tract. The cells
TUMOR encapsulated
have high activity of an enzyme that converts ifosfamide into its active
(cancer-killing) form. In actual practice, the encapsulated cells are first
implanted using radiography, in the blood supply to the pancreas near
that organ and thus the tumor itself. Ifosfamide is then administered at
1/3 the normal dose. Doubling of patients’ median survival time and oneyear survival rate (as compared to historical data for Gemzar®, the only
single-agent treatment approved for advanced pancreatic cancer) were
seen in Phase 2 clinical trials, with no serious treatment-related side effects.
nuvilex.com
Notice Regarding Forward-Looking Statements -- This fact sheet contains forward-looking statements as that term is defined in Section 27A of the United States
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this fact-sheet, which are not purely historical, are forward-looking
statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in
any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of publication of this fact sheet, and we assume
no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking
statements. Although we believe that the beliefs, plans, expectations and intentions contained in this fact sheet are reasonable, there can be no assurance that such
beliefs, plans, expectations or intentions will prove to be accurate.